⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL877784 | 0.86 | — | — | |
| SCHEMBL878490 | 0.86 | — | — | |
| SCHEMBL2305857 | 0.83 | — | — | |
| SCHEMBL23453473 | 0.78 | — | — | |
| SCHEMBL14941325 | 0.78 | — | — | |
| SCHEMBL14941702 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL17824823 | 0.59 | — | — | |
| SCHEMBL1652805 | 0.58 | — | — | |
| SCHEMBL18613719 | 0.58 | — | — | |
| Hydrochloric Acid SCHEMBL18729855 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-02-13 | — | — | US | claimed |
| WO-2021113479-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-06-10 | — | — | WO | claimed |
| US-20210171535-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-06-10 | — | — | US | claimed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | claimed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | claimed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | claimed |
| US-20090306053-A1 | Highly selective rho-kinase inhibitor | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2009-12-10 | — | — | US | claimed |
| US-20090099157-A1 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | claimed |
| EP-1878732-B1 | HIGHLY SELECTIVE Rho-KINASE INHIBITOR | WESTERN THERAPEUTICS INST INC (JP) | 2009-02-25 | — | — | EP | claimed |
| WO-2008100621-A2 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| EP-0757677-B1 | BENZOCYCLOHEXYLIMIDAZOLETHIONE DERIVATIVES | SYNTEX LLC (US) | 2003-06-18 | — | — | EP | claimed |
| US-20030050246-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-13 | — | — | US | claimed |
| US-20030045477-A1 | Peptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-03-06 | — | — | US | claimed |
| WO-2003011896-A1 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-02-13 | — | — | WO | claimed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | claimed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | claimed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | claimed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | claimed |
| EP-0594656-A1 | 4-AMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES | SANDOZ LTD. (CH) | 1994-05-04 | — | — | EP | claimed |
| WO-1993001166-A1 | 4-AMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES | SANDOZ LTD. (CH) | 1993-01-21 | — | — | WO | claimed |